These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 14510059)

  • 1. Surveillance of invasive meningococcal disease in Queensland, 2002.
    Pugh RE; Smith H; Young M
    Commun Dis Intell Q Rep; 2003; 27(3):342-51. PubMed ID: 14510059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced surveillance scheme for suspected meningococcal disease in five regional health authorities in England: 1998.
    Davison KL; Crowcroft NS; Ramsay ME; Begg NT; Kaczmarski EB; Stuart JM; White JM; Orr H;
    Commun Dis Public Health; 2002 Sep; 5(3):205-12. PubMed ID: 12434690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EpiReview: Meningococcal disease in NSW, 1991-2011: trends in relation to meningococcal C vaccination.
    Passmore E; Ferson MJ; Tobin S
    N S W Public Health Bull; 2013 Dec; 24(3):119-24. PubMed ID: 24360208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005.
    Can Commun Dis Rep; 2007 Jun; 33(10):1-15. PubMed ID: 17691125
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
    Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in invasive meningococcal disease in Queensland: a success for immunisation.
    Slinko VG; Sweeny A
    Commun Dis Intell Q Rep; 2007 Jun; 31(2):227-32. PubMed ID: 17725000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
    Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
    Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Community cluster of meningococcal disease by Neisseria meningitidis serogroup C in Andalusia, Spain, March to May 2011.
    Mayoral Cortés JM; Torres Butrón E; García Fernández M; Herrador Ortiz Z; Huarte Osakar S; Santos Luque R; Pérez Morilla E; Guillén Enriquez J
    Euro Surveill; 2012 Sep; 17(36):20261. PubMed ID: 22971329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of meningococcal serogroup C conjugate vaccine in Scotland.
    Mooney JD; Christie P; Robertson C; Clarke SC
    Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and meningococcal serogroup distribution in the United States.
    Hershey JH; Hitchcock W
    Clin Pediatr (Phila); 2010 Jun; 49(6):519-24. PubMed ID: 20507868
    [No Abstract]   [Full Text] [Related]  

  • 11. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003.
    Can Commun Dis Rep; 2006 Apr; 32(8):97-107. PubMed ID: 16685767
    [No Abstract]   [Full Text] [Related]  

  • 12. Enhanced surveillance for meningococcal disease in Queensland in 1999.
    Ward J; Hanna JN; Bates JR; Selvey LA
    Commun Dis Intell; 2000 Nov; 24(11):332-5. PubMed ID: 11190814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance of invasive meningococcal disease in the Czech Republic.
    Kriz P
    Euro Surveill; 2004 Nov; 9(11):37-9. PubMed ID: 15591689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients].
    de Greeff SC; de Melker HE; Spanjaard L; van den Hof S; Dankert J
    Ned Tijdschr Geneeskd; 2003 Jun; 147(23):1132-5. PubMed ID: 12822525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive bacterial diseases: national surveillance in Italy and vaccination coverage in the Local Health Agency 4 "Chiavarese", Liguria region (Italy).
    Trucchi C; Zoppi G
    J Prev Med Hyg; 2012 Jun; 53(2):120-4. PubMed ID: 23240174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012.
    Sadarangani M; Scheifele DW; Halperin SA; Vaudry W; Le Saux N; Tsang R; Bettinger JA;
    Clin Infect Dis; 2014 Nov; 59(9):1208-15. PubMed ID: 25069868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Public health management in invasive meningococcal diseases].
    Ehrhard I; Arndt U
    Gesundheitswesen; 2004 Dec; 66(12):790-5. PubMed ID: 15609213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the aetiology of and evaluating the impact of the Men C vaccination programme on probable meningococcal disease in England and Wales.
    Granerod J; Davison KL; Ramsay ME; Crowcroft NS
    Epidemiol Infect; 2006 Oct; 134(5):1037-46. PubMed ID: 16492318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the burden of serogroup C meningococcal disease in England and Wales.
    Davison KL; Ramsay ME; Crowcroft NS; Lieftucht A; Kaczmarski EB; Trotter CL; Gungabissoon U; Begg NT
    Commun Dis Public Health; 2002 Sep; 5(3):213-9. PubMed ID: 12434691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.